HLA-Haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 3, 2014, Pages 314-318

  Zeidan, Amer M ^a   Forde, Patrick M ^a   Symons, Heather ^a   Chen, Allen ^a   Smith, B Douglas ^a   Pratz, Keith ^a   Carraway, Hetty ^a   Gladstone, Douglas E ^a   Fuchs, Ephraim J ^a   Luznik, Leo ^a   Jones, Richard J ^a   Bolaños Meade, Javier ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bone marrow transplantation (BMT); Donor lymphocyte infusion (DLI); Haploidentical; Human leukocyte antigen (HLA); Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE DISEASE; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LYMPHOMA; ADULT; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HLA HAPLOIDENTICAL BONE MARROW TRANSPLANTATION; HLA HAPLOIDENTICAL DONOR LYMPHOCYTE INFUSION; HODGKIN DISEASE; HUMAN; IMMUNOPROPHYLAXIS; LEUKEMIA RELAPSE; LYMPHOBLASTOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PLASMACYTOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL CANCER; POSTOPERATIVE COMPLICATION; PROLYMPHOCYTIC LEUKEMIA; T CELL PROLYMPHOCYTIC LEUKEMIA; WHOLE BODY RADIATION; YOUNG ADULT;

BONE MARROW TRANSPLANTATION (BMT); DONOR LYMPHOCYTE INFUSION (DLI); HAPLOIDENTICAL; HUMAN LEUKOCYTE ANTIGEN (HLA); STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, ISOGENEIC;

EID: 84896855471     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.020     Document Type: Article

References (24)

1. Huff C.A., Fuchs E.J., Smith B.D., et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006, 12:414-421.
2. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
3. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
4. Alyea E.P., Soiffer R.J., Canning C., et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998, 91:3671-3680.
5. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. JClin Oncol 1997, 15:433-444.
6. Baurmann H., Nagel S., Binder T., et al. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood 1998, 92:3582-3590.
7. Gardiner N., Lawler M., O'Riordan J.M., et al. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Bone Marrow Transplant 1998, 21:711-719.
8. Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206-4211.
9. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
10. Luznik L., Jones R.J., Fuchs E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010, 17:493-499.
11. Wang Y., Liu D.H., Liu K.Y., et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without invitro T cell depletion for the treatment of leukemia: Nine years of experience at a single center. Cancer 2013, 199:978-985.
12. Huang X.J. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Best Pract Res Clin Haematol 2011, 24:351-358.
13. Luznik L., Fuchs E.J. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010, 47:65-77.
14. Symons HJ, Chen AR, Luznik L, etal. Myeloablative haploidentical bone marrow transplantation with T cell replete grafts and post-transplant cyclophosphamide: results of a phase II clinical trial. ASH Annual Meeting Abstracts. Blood 2011;118:4151.
15. Munchel A., Kesserwan C., Symons H.J., et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 2011, 3(Suppl 2):e15.
16. Huang X.J., Liu D.H., Liu K.Y., et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007, 92:414-417.
17. Chang Y.J., Huang X.J. Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?. Blood Rev 2013, 27:55-62.
18. Yan C.H., Liu D.H., Xu L.P., et al. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant 2012, 26:868-876.
19. Matzinger P., Bevan M.J. Induction of H-2-restricted cytotoxic T cells: invivo induction has the appearance of being unrestricted. Cell Immunol 1977, 33:92-100.
20. Durakovic N., Radojcic V., Skarica M., et al. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood 2007, 109:4564-4574.
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
22. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
23. Lewalle P., Triffet A., Delforge A., et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant 2003, 31:39-44.
24. Or R., Hadar E., Bitan M., et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1295-1301.